Sainio Annele, Järveläinen Hannu
University of Turku, Turku, Finland.
University of Turku, Turku, Finland; Satakunta Central Hospital, Pori, Finland.
Adv Pharmacol. 2018;81:209-240. doi: 10.1016/bs.apha.2017.09.008.
The extracellular matrix (ECM) forms the structural basis for the functional properties of different organs and tissues including the vasculature. Consequently, any alteration in the ECM may significantly influence the function of organs and tissues in question. This is also true for the cardiovascular system and its pathologies. Thus, therapies specifically targeting the ECM are likely very potent in the treatment of various diseases. Unfortunately, so far there are no therapies in clinical use primarily targeting the ECM. Nevertheless, most cardiovascular drugs are known to modulate the ECM and its macromolecules. However, their effects on the cardiovascular ECM are neither potent nor specific enough. Therefore, novel ECM targeting pharmacotherapies are desired. Here, the ECM of the cardiovascular tissue in health and disease as well as the effect of current cardiovascular drugs on the ECM are discussed in more detail. Furthermore, potential future pharmacotherapies targeting the ECM of the vasculature in various pathologies are presented.
细胞外基质(ECM)构成了包括脉管系统在内的不同器官和组织功能特性的结构基础。因此,ECM的任何改变都可能显著影响相关器官和组织的功能。心血管系统及其病理状况亦是如此。因此,专门针对ECM的疗法在治疗各种疾病方面可能非常有效。不幸的是,到目前为止,临床上尚无主要针对ECM的疗法。然而,大多数心血管药物已知可调节ECM及其大分子。然而,它们对心血管ECM的作用既不够强大也不够特异。因此,需要新型的靶向ECM的药物疗法。在此,将更详细地讨论健康和疾病状态下心血管组织的ECM以及当前心血管药物对ECM的影响。此外,还介绍了未来针对各种病理状况下脉管系统ECM的潜在药物疗法。